APA citiranje

Borthakur, G., Popplewell, L., Boyiadzis, M., Foran, J., Platzbecker, U., Vey, N., . . . Kantarjian, H. (2016). Activity of the oral MEK inhibitor trametinib in RAS-mutant relapsed or refractory myeloid malignancies. Cancer.

Citação norma Chicago

Borthakur, Gautam, et al. "Activity of the Oral MEK Inhibitor Trametinib in RAS-mutant Relapsed or Refractory Myeloid Malignancies." Cancer 2016.

MLA citiranje

Borthakur, Gautam, et al. "Activity of the Oral MEK Inhibitor Trametinib in RAS-mutant Relapsed or Refractory Myeloid Malignancies." Cancer 2016.